Background
The legal proceedings stem from a complex and lengthy pharmaceutical litigation involving several hundred claimants against GlaxoSmithKline UK Limited concerning its anti-depressant medication Seroxat. The claim, originally commenced on 30 April 2004, represented a substantial group litigation alleging the medication was defective and had caused harm to the claimants.
The litigation’s procedural history reveals significant challenges and transformations. Initially publicly funded, the claim underwent dramatic changes when the Legal Services Commission discharged the public funding certificate in November 2010, following counsel’s advice questioning the claim’s merits. This decision precipitated a significant reduction in claimant numbers, with 369 discontinuing their claims while 124 challenged the decision.
By January 2015, a review panel had conclusively rejected the claimants’ challenge, effectively terminating their public funding. The litigation’s landscape shifted dramatically when Fortitude Law entered as legal representatives for 102 claimants in July 2015, signalling new funding arrangements involving discussions with external funders and insurers.
A pivotal moment occurred on 19 November 2015 when Brit UW Limited issued an after-the-event (ATE) legal expenses policy to the claimants. This policy, providing potential cost protection up to £750,000, became a critical factor in the court’s deliberations about whether the proceedings could continue.
The trial, which commenced on 29 April 2019 before Lambert J, was effectively concluded within three days when a fundamental issue regarding the claimants’ case on defect was decided in the defendant’s favour. By 7 May 2020, the claimants submitted to judgment, with only costs arguments remaining unresolved.
Lambert J’s order on 3 July 2020 was particularly significant, ordering the claimants to pay costs on an indemnity basis and setting a crucial deadline of 31 July 2020 for any non-party costs order (NPCO) applications. This deadline became the focal point of the current legal dispute.
Costs Issues Before the Court
The primary costs issue centred on the defendant’s application for an extension of time to pursue a non-party costs order (NPCO) against Brit UW Limited, the ATE insurer. The critical questions were whether the original order carried an implied sanction for non-compliance and, if not, whether the court should exercise its discretion to grant a substantial time extension.
The Parties’ Positions
The defendant argued that no implied sanction existed in Lambert J’s original order, and therefore the application should be assessed under the overriding objective rather than the stringent Denton test. They contended that until Brit’s communication on 25 May 2023, there was no apparent need for an NPCO application.
Conversely, Brit argued that the order carried an implied sanction, necessitating the application of the Denton test. They emphasized the defendant’s significant delay, lack of urgency, and failure to proactively manage the potential NPCO application within the originally prescribed timeframe.
The Court’s Decision
The court comprehensively rejected the defendant’s application, finding that while no strict implied sanction existed, the defendant had failed to demonstrate a justifiable reason for the extensive delay. The judgment highlighted the defendant’s slow progression, missed opportunities to seek timely extensions, and lack of urgency in pursuing the potential NPCO.
Crucially, the court emphasized that the original order was designed to expeditiously resolve residual litigation matters. The defendant’s failure to promptly consider and address the potential NPCO application, despite known complexities surrounding the ATE insurance, was a significant factor in the court’s decision to refuse the time extension.















